<SEC-DOCUMENT>0001558370-23-007746.txt : 20230503
<SEC-HEADER>0001558370-23-007746.hdr.sgml : 20230503
<ACCEPTANCE-DATETIME>20230503083604
ACCESSION NUMBER:		0001558370-23-007746
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230503
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230503
DATE AS OF CHANGE:		20230503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		23881865

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>glyc-20230503x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.5.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/2/2023 9:32:17 PM -->
      <!-- iXBRL Library version: 1.0.8476.13996 -->
      <!-- iXBRL Service Job ID: c542d899-f6cf-4eee-a008-a9473c8d36fc -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:glyc="http://www.glycomimetics.com/20230503" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:EntityCentralIndexKey" id="Tc_MnxP6RNrlEGr1_0do4e9Lg_2_1">0001253689</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:AmendmentFlag" id="Tc_eaL_CUD2mE-dDDJVWi9lCA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="glyc-20230503.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-03</xbrli:startDate><xbrli:endDate>2023-05-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-top:9pt double #000000;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><a id="_be6ce6e7_18ef_4b74_9739_0208f27c35e1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">UNITED STATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">FORM </b><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:DocumentType" id="Narr_m7fGUoi-OUKUvWRqvFnJIQ"><b style="font-weight:bold;letter-spacing:-0.1pt;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Pursuant to Section 13 or 15(d) of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;">Date of Report (Date of earliest event reported):</b><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_UhYOneEewEWBnRE76J-X2Q"><b style="font-size:9pt;font-weight:bold;">May 3, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:EntityRegistrantName" id="Narr_8CjUNTOhKUeVW6y9n98BdA"><b style="font-weight:bold;letter-spacing:-0.1pt;">GlycoMimetics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Exact name of registrant as specified in its charter)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_e1f4de58_61bd_4709_b865_8049cd6378dd"></a><a id="Tc_jDdOMbd7r0WhSZA12bnXww_2_0"></a><a id="Tc_NFk78L9o9UKJyPxZYXqqTA_2_2"></a><a id="Tc_2fT6V7ylAEeeuvWxlRvAEA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_JIwmX19kXU-70_58BM5YpQ_1_0"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:EntityFileNumber" id="Tc_c6ygeAXRoECaitoyX-xAfg_1_2"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">001-36177</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:EntityTaxIdentificationNumber" id="Tc_BLVu67dPWESoLCGrFOl7EQ_1_4"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">06-1686563</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(State or other jurisdiction of</span> <span style="letter-spacing:-0.1pt;">incorporation)</span></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Commission File Number)</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(IRS Employer</span><br /><span style="letter-spacing:-0.1pt;">Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:EntityAddressAddressLine1" id="Narr_3SjEJc-_30-B-2ctpm1WRg"><b style="font-size:9pt;font-weight:bold;">9708 Medical Center Drive</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:EntityAddressCityOrTown" id="Narr_Jw6Diya9mUmRmG8a2jX5Jw"><b style="font-size:9pt;font-weight:bold;">Rockville</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:EntityAddressStateOrProvince" id="Narr_KECTPm4kKkOJtipXs8OjnA"><b style="font-size:9pt;font-weight:bold;">MD</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:EntityAddressPostalZipCode" id="Narr_ccTkYrTNckG1i19wOZAUaQ"><b style="font-size:9pt;font-weight:bold;">20850</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Address of principal executive offices, including zip code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:CityAreaCode" id="Narr_itY3SpLxREa513uguBrzxQ"><b style="font-size:9pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:LocalPhoneNumber" id="Narr_QvKSMySvOU-XLjuqX197Sg"><b style="font-size:9pt;font-weight:bold;">243-1201</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Former name or former address, if changed since last report)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_HWJRufdh8ESlugMqX9FHrw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_goUQblZ4p0OjGnEDKJUFRw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr__9Yt3yyxaUKbQOZ1_bw6uw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_YND-7qvL70mk-SmFlNxTEA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;letter-spacing:0pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;letter-spacing:0pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_815aaab8_f3ad_460f_b7c2_43bd0f552b4c"></a><div style="margin-left:0pt;"><a id="Tc_DPiP5mvA90qIJDyhZacZCQ_1_0"></a><a id="Tc_yAXrnp6a3kOV6o6CW-CxGQ_1_1"></a><a id="Tc_uIhYECqzgUyW1OcDhhrNfA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:97.55%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of each class</b></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:44.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:Security12bTitle" id="Tc_ysHuWJ1U7kGD3tXCdHhVFw_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" name="dei:TradingSymbol" id="Tc_Vccp7K-JpkeMhZ-h3G_1KQ_2_1"><span style="font-size:9pt;">GLYC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:44.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_i_xTSXPqs0Cd0aJf8RVX0Q_2_2"><span style="font-size:9pt;">The Nasdaq Stock Market</span></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_Gy1qAVdv502bSsIdyiz2ag"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> <span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-bottom:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Courier New';line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:81.18%;border:0;margin:30pt 9.41% 30pt 9.41%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_612e95bc_540c_49b0_9c61_915d324c8dfd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 2.02 &#160;</b></span><b style="font-weight:bold;">Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On May 3, 2023, GlycoMimetics, Inc. (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span><i style="font-style:italic;">&#8221;)</i><span style="font-style:italic;font-weight:bold;"> </span>issued a press release announcing its financial results for the first quarter ended March 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Exchange Act</span>&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company&#8217;s filings under the Securities Act of 1933, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Securities Act</span>&#8221;), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01</b></span><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (d)&#160;Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:88.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.27%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">9</span>9.1</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20230503xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated May 3, 2023, &#8220;GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023&#8221;</span></a> </p></td></tr><tr><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.05pt;margin:0pt;"><span style="font-size:0.05pt;visibility:hidden;">&#8203;</span></p><a id="_d0ff95cd_5fa8_4d74_b328_f4512d562478"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;text-align:justify;text-indent:37.05pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.7pt;padding-right:0.7pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></div></div></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GLYCOMIMETICS, INC.</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;">By:&#160;&#160;</span></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">/s/ </span>Brian M. Hahn</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:-0.1pt;white-space:pre-wrap;">Date:  </span>May 3, 2023</p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian M. Hahn<br />Senior Vice President and Chief Financial Officer </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>glyc-20230503xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/2/2023 09:32:16 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 99.1</b></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;text-transform:uppercase;margin:0pt 41.75pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"><img src="glyc-20230503xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:58.4pt;width:271pt;"></b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Pivotal Phase 3 study of uproleselan combined with cytarabine-based chemotherapy in relapsed/refractory (R/R) acute myeloid leukemia (AML) continues to be projected to reach final survival event trigger within first half of 2024 </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Cash and cash equivalents expected to fund current operations into late 4</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;">th</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> quarter of 2024</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Conference call and webcast today at 8:30 a.m. ET </font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">ROCKVILLE, Md.--(BUSINESS WIRE) &#8211; May 3, 2023-- GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the first quarter ended March 31, 2023. Cash and cash equivalents as of March 31, 2023 were $65.0 million.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#8220;Thanks to the outstanding work of our team preparing the clinical trial database and evaluating the data from the recent interim utility analysis of our Phase 3 study of uproleselan in R/R AML, GlycoMimetics is well positioned to expeditiously complete final trial analysis following the final survival events trigger, which is projected to occur within the first half of 2024,&#8221; said Harout Semerjian, Chief Executive Officer of GlycoMimetics. &#8220;We are optimistic and excited about the potential of uproleselan to improve overall survival in R/R AML and are fully focused on delivering on the potential of this important first-in-class therapy for patients in need of new, more effective treatment options.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Operational Highlights </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><a name="_Hlk130828815"></a><b style="font-weight:bold;">Uproleselan</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In February 2023, GlycoMimetics announced that the independent Data Monitoring Committee for its ongoing Phase 3 trial of uproleselan in R/R AML had conducted an interim utility analysis (IA) and subsequently recommended the study should continue to the originally planned final overall survival events trigger. A statistical plan to add an IA to the Phase 3 study was cleared with the FDA in the fourth quarter of 2022, which enabled the DMC to review efficacy data from that study at around 80% of planned survival events. The IA utilized a very conservative threshold to preserve the statistical integrity of the originally planned final overall survival analysis. The overall survival events trigger is projected to occur within the first half of 2024.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The NCI Alliance for Clinical Trials in Oncology will conduct a planned interim analysis of event-free survival in 267 patients randomized to its Phase 2/3 clinical trial evaluating uproleselan in newly diagnosed older adults with AML who are fit for chemotherapy. When available, the company will share these interim analysis results. </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;line-height:1.37;margin-bottom:10pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Quarter 2023 Financial Results:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Cash position: As of&#160;March 31, 2023,&#160;GlycoMimetics&#160;had cash and cash equivalents of&#160;$65.0 million&#160;as compared to&#160;$47.9 million&#160;as of&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">December 31, 2022.  During the quarter the Company raised $28.7 million dollars from sales of shares of common stock under its existing ATM facility. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">R&amp;D Expenses: The Company&#8217;s research and development expenses decreased to&#160;$5.4 million&#160;for the quarter ended&#160;March 31, 2023,&#160;as compared to&#160;$9.6 million&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">for the same period in 2022.  The decreased expenses were primarily due to lower clinical trial and development costs related to our global Phase 3 clinical trial of uproleselan in individuals with relapsed/refractory AML, which completed enrollment in November 2021.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">G&amp;A Expenses: The Company&#8217;s general and administrative expenses increased to&#160;$5.5 million&#160;for the quarter ended&#160;March 31, 2023,&#160;as compared to&#160;$5.1 million&#160;for the same period in 2022, primarily due to commercial readiness expenses for uproleselan and additional patent fees.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Shares Outstanding: Shares of common stock outstanding as of March 31, 2023, were 64,245,224.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 36pt;"><font style="margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="white-space:pre-wrap;">The Company will host a conference call and webcast today at 8:30 a.m. ET.   To access the call by phone, please go to this </font>registration link and you will be provided with dial in details.&#160;Participants are encouraged to connect 15 minutes in advance of the scheduled start time. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;">A live webcast of the call will be available on the &#8220;Investors&#8221; tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">About Uproleselan</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">Discovered and developed by GlycoMimetics, uproleselan is an investigational first-in-class, E-selectin antagonist. Uproleselan (yoo&#8217; pro le&#8217;se lan), currently in a comprehensive Phase 3 development program in acute myeloid leukemia (AML), has received Breakthrough Therapy designation from the U.S. FDA and from the Chinese National Medical Products Administration for the treatment of adult AML patients with relapsed or refractory disease. Uproleselan is designed to block E-selectin binding and stimulation of myeloid cells. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells confers a pro-survival effect. Uproleselan intends to provide a novel approach to disrupting established mechanisms of leukemic cell resistance. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">About GlycoMimetics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases with high unmet needs. The Company&#8217;s science is based on an understanding of the role that carbohydrates play in cell recognition and its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates, with the goal of developing transformative therapies for diseases with high unmet need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more atwww.glycomimetics.com.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">This press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of and data from clinical trials, planned or potential clinical development, regulatory submissions and commercialization activities, potential benefits and impact of the Company&#8217;s drug candidates, and the Company&#8217;s expected cash runway. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing&#160;GlycoMimetics, please see the risk factors described in the Company&#8217;s Annual Report on Form 10-K filed with the&#160;U.S. Securities and Exchange Commission&#160;(SEC) on&#160;March 29, 2023, and other filings&#160;GlycoMimetics&#160;makes with the&#160;SEC&#160;<font style="white-space:pre-wrap;">from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.  </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investor Contact: </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Argot Partners</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Leo Vartorella </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;">212-600-1902</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;">Glycomimetics@argotpartners.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">Public Relations Contact:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;">Eliza Schleifstein</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;">G. Stone Connections, LLC</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">917-763-8106</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">Condensed Statements of Operations</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">(In thousands, except share and per share data)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 41.75pt;"><font style="visibility:hidden;margin:24pt 0pt 18pt 0pt;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;">Research and development expense</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5,419</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 9,604</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;">General and administrative expense</p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5,522</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5,056</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 30pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 30pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 10,941</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,660</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (10,941)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (14,660)</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Interest income </p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 582</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 7</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (10,359)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (14,653)</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Net loss per common share &#8211; basic and diluted</p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.17)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.28)</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding &#8211; basic and diluted</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 60,350,127</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 52,331,391</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">Balance Sheet Data</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">(In thousands)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><font style="font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 65,002</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 47,871</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Working capital</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 61,346</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 41,834</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 68,922</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 51,811</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 6,740</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8,881</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#39; equity</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 62,181</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 42,930</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>glyc-20230503xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20230503xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !. 6D# 2(  A$! Q$!_\0
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MUL<'(Y##K[Y%>=>#O!_A7Q#I(FO_ !*-*OD)$L$^Q!UX*EC\W&/?.:ZCX?\
M@OPI<^*()M)\237=Y8RB80O!L\P*1D@GJ.>U=6)IX=1J0E'1;6@U;M[W7]3C
MPM3$N=.<97;>MYIW77W>C_(X_4H_%@^(MNMU(I\3[X_+?$6,[?EZ#;T]J[;4
M/$FMV?Q.\-6%Y) ;@PVD=R?LL+.'8#S 'VY ))^Z<<\5!XB_Y."L?^ND'_HL
M4>-/^2\Z/_UTMON_6M')5>12BOX;>W]:&:A*BIN,W_$2W_/S-[XF?%*_TC64
M\/\ A^(2ZFVT22[-Y5F^ZJKW/(//K7/S7'Q6T",7\WFW41(W0[8INN."J\C\
M*JZS>+X(^.#ZEJD1^QR2&19 N?D=-H8>NTY!^AKT_4OBSX6TVT$YU6*ZR0!%
M;?.YS[=L=>?3UXKB<7AX4XT:*FI)-MJ]V^GD=RDL3.K*O7<'%M))VLEU\[F=
MXR\=ZMX<^'EOJDNG"QU>Y98/*<AUA8ACO[]EX!Z$C/3GC_!VK_$6\N]+ODF3
M5-.O7^?>\9C0#[V\J,QG _I@GBN_\7^(O"^H^"3=ZG.MUH]YA8S$#O=L_P
MX(8$'Z8.:\4OKA/AOK5G?>%O$*:E;7 WF)#\P4$?)*O3G/'0]>!Q1@Z<:E*4
M%32DV]TVO2_2P8ZI*E6A4=5N"2VDD_6W6Y].45FZEXBT_18K1]2NH['[4XCC
M$S8^;&<$]NG4\=/45H@A@"#D'D$5\VXM)-K<^I4HMM)ZH^0?V\?^2E?LQ_\
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MW\%_!GQS\+/X?\:Z';ZUIV[S(C)E9;>3&-\4BX9&]P>1P<@D5VU% 'RMI/\
MP3:^$%GJ%E+J<GB;Q/863;[?2-;UEYK.,CH!&H4X XP3C'!R*^CM8\'Z7K/A
MZ/1)+<6VF1*B1V]H!$L:IC:J@# 48  'I6W151DX-2B[-$SBJD7&:NF9V@Z#
M:>'-'@TRS5A:0A@JR'<>6+')^I-9/A?X<Z+X/U">\TV*1)ID,;%WW *2#@>G
M('Y5T]%:>VJ>][S][?S]3/V-/W7RKW=O+T.:U_X>Z1XCUNUU:[27[;;! C1R
M;1\K%AD=^32Q_#_28O%I\1A9CJ9);<9/DY39T^AKI**:KU4N52=K6^78EX>B
MY<SBKWO\UU.;M? &DV?BJ3Q#&LPU&0L6)D^3YA@\?2CQ;\/])\:R6SZFLS&W
M#*GE2;1SC/\ (5TE%"KU5)34G=:+T!X>BX.#BK-W:[LSM8T&UUS19=*N@YM9
M4"-M;#8!!'/X"HO#?ABQ\*Z4-.L5<6P9FQ(VXY/7FM:BH]I/DY+Z;V\S3V<.
M?VEM;6OY' ZI\$/"^IW33K!/9%CDI:R[4S]"#C\.*Z#PMX'T?P="R:9:B.1Q
MAYW.Z1_8L>WL,"MZBM9XFO4AR2FVO4PAA*%.?M(02?>QS=UX TF\\51^(9%F
M.HQE2I$GR?*,#CZ4:AX TG4_$UOKTRS?VA 4*%9,+\O3(KI**E5ZJM[ST5OE
MV+>'HN]XK5W^??U,?Q+X3TOQ=9K;:I:BX1#N1P2KH>^&'(^G0UR=I\"/"UM<
M+*Z7=RJG/E33?*?K@ _K7HE%53Q->E'DA-I>I-3"T*TN>I!-^ACZQX2TG7='
M72[RRC>RC $<:#;Y6!@%2.F/:N<T;X+^&=%U".\2&>YDB8.BW,FY5(Z'  S^
M.:[NBE#$5J<7"$VD_,<\-0J24YP3:\CS_P 5^"+[QAX]TN:]2,^'K&(R!=P)
MDDR"5*]><+[84^M>@445-2M*I&,7M%615.C&E*4UO)W?]=D<'\2_@KX9^+.K
M^#M2\017,EUX4U:+6=-,$YC"W$;*REQ_$N5'%&L?!7PSKGQAT'XF745R?%.B
MV,NG6DBSD1"&3?N#)T)_>-S7>45B;E/6=*M]=TB^TVZ#&UO('MY0IP2CJ5;!
M['!-<_\ #'X8Z%\)/A]I7@O0(95T+38GA@BNI/-?:SL[!F/7EVKK** /F?7_
M /@GM\*=1U^\U;0G\1> Y;TLUU;^$]7>RMY2W!_=X95&"1M3:N">*]!^"/[+
MWPY_9\6ZE\(:$(=5O 5N]8OI6N;VX!.2&E?D D E5P"0"1D5ZO10!Y+<?LP>
M![G]H6U^,[P7W_":6]L;=&%R1;<PM!O,>.6\IBO7'?&>:]:HHH **** //?C
M+\ ? ?Q]\/\ ]D>-O#]MJT: _9[K'EW5J?6*5?F3W .#CD$<5\0ZI^SM\??V
M'[JYU3X0:O+\3?ALS,]WX2OXO.E6,D[@8!]XD'_60;68_>3:.?T@HH&?F+X8
M\1?'S]L'21X;^%WA&Q^ 7PI9B+R[L8C;"9R<3!)%1&DR<C;$JCL[5]8?LX_L
M*_#;]G00:C:61\2^+E^9_$.K('F1NYA3E81UY&6YY8U]%44 %%%% @HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>glyc-20230503.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/2/2023 9:32:20 PM-->
<!--Modified on: 5/2/2023 9:32:20 PM-->
<xsd:schema targetNamespace="http://www.glycomimetics.com/20230503" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:glyc="http://www.glycomimetics.com/20230503" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20230503_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20230503_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="glyc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>glyc-20230503_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/2/2023 9:32:20 PM-->
<!--Modified on: 5/2/2023 9:32:20 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="glyc-20230503.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="glyc_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>glyc-20230503_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/2/2023 9:32:20 PM-->
<!--Modified on: 5/2/2023 9:32:20 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="glyc-20230503.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="glyc-20230503.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638186599406753010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638186599406753010" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638186599406753010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638186599406753010" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638186599406753010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638186599406753010" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638186599406763023" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638186599406763023" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638186599406763023" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638186599406763023" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638186599406763023" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_638186599406763023" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638186599406763023" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638186599406763023" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638186599406763023" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638186599406763023" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638186599406763023" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638186599406763023" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638186599406763023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638186599406763023" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638186599406773016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638186599406773016" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638186599406773016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638186599406773016" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638186599406773016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638186599406773016" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638186599406773016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638186599406773016" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638186599406773016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638186599406773016" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638186599406773016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638186599406773016" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140366289318208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  03,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9708 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLYC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>glyc-20230503x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="glyc-20230503.xsd" xlink:type="simple"/>
    <context id="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Tc_MnxP6RNrlEGr1_0do4e9Lg_2_1">0001253689</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Tc_eaL_CUD2mE-dDDJVWi9lCA_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_m7fGUoi-OUKUvWRqvFnJIQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_UhYOneEewEWBnRE76J-X2Q">2023-05-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_8CjUNTOhKUeVW6y9n98BdA">GlycoMimetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Tc_JIwmX19kXU-70_58BM5YpQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Tc_c6ygeAXRoECaitoyX-xAfg_1_2">001-36177</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Tc_BLVu67dPWESoLCGrFOl7EQ_1_4">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_3SjEJc-_30-B-2ctpm1WRg">9708 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_Jw6Diya9mUmRmG8a2jX5Jw">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_KECTPm4kKkOJtipXs8OjnA">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_ccTkYrTNckG1i19wOZAUaQ">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_itY3SpLxREa513uguBrzxQ">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_QvKSMySvOU-XLjuqX197Sg">243-1201</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_HWJRufdh8ESlugMqX9FHrw">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_goUQblZ4p0OjGnEDKJUFRw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr__9Yt3yyxaUKbQOZ1_bw6uw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_YND-7qvL70mk-SmFlNxTEA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Tc_ysHuWJ1U7kGD3tXCdHhVFw_2_0">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Tc_Vccp7K-JpkeMhZ-h3G_1KQ_2_1">GLYC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Tc_i_xTSXPqs0Cd0aJf8RVX0Q_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw"
      id="Narr_Gy1qAVdv502bSsIdyiz2ag">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M@42C5J->JW7N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ @42C5IE<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "!1*-66OCA
MU4H$  "K$   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ @42C5I^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  [1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="glyc-20230503x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="glyc-20230503x8k.htm">glyc-20230503x8k.htm</File>
    <File>glyc-20230503.xsd</File>
    <File>glyc-20230503_lab.xml</File>
    <File>glyc-20230503_pre.xml</File>
    <File>glyc-20230503xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "glyc-20230503x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "glyc-20230503x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "glyc-20230503_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glyc-20230503_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "glyc-20230503.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "glyc",
   "nsuri": "http://www.glycomimetics.com/20230503",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20230503x8k.htm",
      "contextRef": "Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20230503x8k.htm",
      "contextRef": "Duration_5_3_2023_To_5_3_2023_fhBC0h-Sm0qitLxTnoGvnw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "glyc_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.glycomimetics.com/20230503",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-23-007746-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-007746-xbrl.zip
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MOT_:__".?=FD"X&@?BAJ>Z)<;ZJ.7M'!M-.FZ102 ]:"C1Q3X+^?G<24I':
M4$7F2QOBQX_?Q_QP')K>?-PL(GA!+,:4W#;:S58#$ EHB,GLMK&*'3\.,&Y\
MO/OYIYM?'.?[_;<!A#18+1#A$##D<Q3"&O,YC.ERZ1-X0HSA*()[AL,9 FBW
MFE[SJGD-CI-YW/NQZ$,))&9>L[UKZ6=^E'3ARO5<K^5UX+K;\;I>"X9/.]V3
M*&^*#PDC3/[KRA\3,2"(F"3N;F)\VYASONRZ[GJ];JX[3<IFHG^K[7Y_&HR"
M.5KX#B8Q]TF &B#TW3@Y.:"!SY,YVNN^F;!(&73<W5A&A7SE*)DC3SEMS^FT
MFYLX;&0ERN8C!E'RS1M]EJE]?7WM)JT[J3 *^4Z[[WOEIHT-,7$ V=3Y$Q0-
MQ!$D+EV^7:+;!MIP1$(DRTW.,AJADG)E<U)SZBR]:9 SC.3$4J;\Y@Q-;QNS
M:!LX\EUM7;4Z<G9^E6=^?,K(ZY'P@7#,MX]D2MDB>6-ZDY@S/^#**"D_=3JV
MGYREHZ;>W861@_18/I'/ E6$.#PP09G"#:@ ;LF=Q%%UGS*Z."U"6@8]H=./
M:!)5SYX+SE!,5RSYW!S/QG[>4]^S7>VBIURO$''^')T0YDX- CX)(1T&]L:!
M?]1(_]ZDE9Y$L2P@5I^T& 7-&7UQ0X3E>N7) XFXE^ M7NP2CX5C848TS9;"
M:@HBF2RV68B>L<2S"9-N-4(T1 Q3\<D)/XE+:DG(HNX"L-)&*_*5$UD.FK[6
MLXE+;<6R%H(TK@&^= 7]C"/T=;68(*;)K)%8C)PID**MV&XI:,8RJS*672JE
M(Z26M='U#<VPO"83_M5?Z%8V@\QZRO3!\J3E-5;39BCU3.)>74':UD;=H[@G
M9DO*DFWAB(OEM$]7A+-MGX9F" _ULI[)HV+G$2WM8C6QQU5^)L"Y03Y ,@Q0
M!ME0(,>JC>JQOWD,Q58!3W'Z[<:!R[99;SW)!Z+F&3:(K:;W4,UG<BOL(>]?
M]X6_%X9BUN+LUP 3U#9.AEYK/:0E$?. :H16PUE6[YE@9IX?U %(=W@F]:VB
MV<!]<?C,QG1-#DU#3GDI4+Z-IT7R578)0&JJ?2\<I;6\L$OSNE%,=A7/;,CH
M"R:!>7]JE%\*E(:@6C(+VDO TU3R>S&ZVWVJ$>H&=4AC[D=_XV7I;91!?"F0
M:D-J$<TI+P%0?<'OA6?J#L*^KMLBN6CW&/(-.!::+090%T0AM]]F*63:$JMB
ME5R)I5M=%,EG!:+AG!+SU^ :B<4TF0(IHHKMEE)E++,J68DA)([UW0W_Q3#G
MB/3I8K$BV;UXK$EKTEG,66DT!9M69"EQY;56Q2YSA;QM#>B-:(0#S#&9/8F-
M(\.^+K-69#%TYE"*N+<*2W$K*;0J:Z^6H#QK &W(D(0;B3<N>1)#/G+&GJ=3
M[;6T5&PQ>(=#*@#-2DM!/*+@JD *:R?8\X;4'!+W^M%\C.,58B<!JNMR.9@:
M QM@?:._#&3-9;\;N.D0=?,[0L%*[!^V;6\RQCS2W>9J)!;S:0JTNWH7VBWE
MSUAF5=X2%Z!3:'N_37X'Y5\#8F/FR_\?&&T7$ZJ+6FRW&"YM%$56KM%2K/0U
M5F8J=8/4KL;5ZF$3S$7)R/#,ET%F,5AEP8HKU[[&4LQ*2ZU\[Y&9@G*M]YFO
MAP5B,T'['XRN^5QL#I8^V1J_$3>I+6;PB)CY/U-HI982>4S%9_ZA0IE#Z@Z9
M?6V ]L4NDOG1H]@_;KX@,YIO==9#:8B6Q[$@LAI$4ZUG(IC90N(+PK@&^'KB
M[B64=S"?(W^F"5QLMQ@V;10%6:[14KCT-5:%:N<&TFX?I1OW=>2!.)+_8)N=
MRGK?_0]02P,$%     @ @42C5HIXA3R&!   OR@  !4   !G;'EC+3(P,C,P
M-3 S7W!R92YX;6S=FEV/XC84AN\K]3^XZ76^%V9 PZX8=K9"'7;0#%57O5F9
MQ(#5Q(YL,\"_KQUBEH^$A*H-"C<0XM?'Y_5C3#C)PZ=U'(%WQ#BFI&>XEF,
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M'[#9]'_(+?=\U*S!G"@'O> (_S-:DLW9V5Q>O(;/ZU;L<X<,;E>&8Z<<.PR
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MV/W[+S%?V&?!L[BPR?9T<.F>#C20'GH;)9639M0U:S^D2:74\SB]+U$M_^&
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M\_5Z%ODHKC6PPW!;)IUB /47!-3W"E /[P'4,0LP?ZD7$QT?[%/&D4ZDYJC
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M8RTR,#(S,#4P,W@X:RYH=&U02P$"% ,4    " "!1*-6,>&\.J,9  #49 $
M&               @ %:)0  9VQY8RTR,#(S,#4P,WAE>#DY9#$N:'1M4$L%
3!@     %  4 30$  #,_      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
